Literature DB >> 17692387

In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis and anti-malarial drugs from Thai flora and microbes.

George A Gale1, Kanyawim Kirtikara, Pattama Pittayakhajonwut, Somsak Sivichai, Yodhathai Thebtaranonth, Chawanee Thongpanchang, Vanicha Vichai.   

Abstract

Malaria continues to be a major infectious disease of the developing world and the problem is compounded not only by the emergence of drug resistant strains but also from a lack of a vaccine. The situation for tuberculosis (TB) infection is equally problematic. Once considered a "treatable" disease for which eradication was predicted, TB has re-emerged as highly lethal, multi-drug resistant strains after the outbreak of AIDS. Worldwide, the disease causes millions of deaths annually. Similarly, treatments for chronic inflammatory diseases such as arthritis have been impeded due to the potentially lethal side effects of the new and widely prescribed non-steroidal anti-inflammatory compounds. Thais have utilized bioresources from plants and some microorganisms for medicine for thousands of years. Because of the need for new drugs to fight malaria and TB, with radically different chemical structures and mode of actions other than existing drugs, efforts have been directed towards searching for new drugs from bioresources. This is also true for anti-inflammatories. Although Thailand is considered species-rich, only a small number of potential bioresources has been investigated. This article briefly describes the pathogenesis of 2 infectious diseases, malaria and TB, and modern medicines employed in chemotherapy. Diversities of Thai flora and fungi and their chemical constituents with antagonistic properties against these 2 diseases are described in detail. Similarly, anti-inflammatory compounds, mostly cyclooxygenase (COX) inhibitors, are also described herein to demonstrate the potential of Thai bioresources to provide a wide array of compounds for treatment of diseases of a different nature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692387     DOI: 10.1016/j.pharmthera.2007.03.016

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  1 in total

1.  4-[2-(1-Acetyl-2-oxopropyl-idene)-hydrazino]-N-(pyrimidin-2-yl)benzene-sulfonamide.

Authors:  Priyanka Rai; Shalini Upadhyay; M Nethaji; K K Upadhyay
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.